Trial · NCT01305213
Results by group46
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 46
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Arm I Bevacizumab | 4.83 | 95% Confidence Interval 4.14 to 6.24 | months | |
| Progression-free Survival (PFS) | Arm II Bevacizumab + Fosbretabulin | 7.23 | 95% Confidence Interval 4.30 to 10.51 | months | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm I Bevacizumab | Thrombocytopenia | 0 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm II Bevacizumab + Fosbretabulin | Thrombocytopenia | 1 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm I Bevacizumab | Neutropenia | 3 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm II Bevacizumab + Fosbretabulin | Neutropenia | 1 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm I Bevacizumab | Other Investigations | 1 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm II Bevacizumab + Fosbretabulin | Other Investigations | 4 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm I Bevacizumab | Other Blood/Lymphatics | 0 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm II Bevacizumab + Fosbretabulin | Other Blood/Lymphatics | 1 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm I Bevacizumab | Cardiac | 1 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm II Bevacizumab + Fosbretabulin | Cardiac | 1 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm I Bevacizumab | Nausea | 2 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm II Bevacizumab + Fosbretabulin | Nausea | 3 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm I Bevacizumab | Vomiting | 0 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm II Bevacizumab + Fosbretabulin | Vomiting | 2 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm I Bevacizumab | Other Gastrointestinal | 5 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm II Bevacizumab + Fosbretabulin | Other Gastrointestinal | 8 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm I Bevacizumab | General and Administration Site | 2 | Participants | |
| Incidence of Adverse Events (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 | Arm II Bevacizumab + Fosbretabulin | General and Administration Site | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01305213/results